JAAPA
Precision oncology in breast cancer
ABSTRACT Recent advances in breast cancer management have transformed treatment across molecular subtypes and expanded the role of precision oncology. Hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–positive (HER2-positive), HER2-low, and triple-negative breast cancer (TNBC) each demonstrate distinct biologic behavior requiring tailored therapeutic strategies. In HR-positive disease, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and next-generation selective estrogen receptor deg …